MedPath

Identification of Risk Factors for Atrial Fibrillation After Ablation of an Atrial Flutter by Radiofrequency of the Cavotricuspid Isthmus.

Completed
Conditions
Flutter
Registration Number
NCT03919097
Lead Sponsor
José Castro
Brief Summary

Atrial flutter is a common condition that is effectively treated by ablation using radiofrequency. Due to its feasibility, effectiveness and low procedural risk, radiofrequency ablation is a first-line treatment of atrial flutter.

Several studies have been published concerning the factors associated with the occurrence of atrial fibrillation during or after flutter ablation, in patients with and without clinical history of atrial fibrillation. 26 to 46% of patients are likely to develop it, according to ECG or Holter diagnoses. The figure rises to more than 50% with a diagnosis with an implantable loop recorder.

In patients without a prior history of atrial fibrillation before ablation, anticoagulants are routinely administered 4-6 weeks after flutter removal by most cardiologists.

Although there are no specific guidelines for anticoagulation after flutter ablation, it is currently recommended to treat the patient as for atrial fibrillation. It is therefore crucial to identify in advance patients at high risk of atrial fibrillation after flutter ablation, in order to assess the appropriateness of maintaining oral anticoagulant therapy.

The objectives of this study are:

* to evaluate the frequency and identify the factors predicting the occurrence of atrial fibrillation after flutter ablation

* to determine the risk of a stroke occurring in patients with atrial fibrillation after flutter ablation.

The database consists in patients of the CHU Brugmann Hospital treated between 1996 and 2018.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
50
Inclusion Criteria

Patients treated at the CHU Brugmann Hospital for flutter ablation by radiofrequency between 1996 and 2018.

Exclusion Criteria

None

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Cardiac surgery antecedentsOne day

Presence of cardiac surgery antecedents at the date of flutter ablation

Age at ablationOne day

Age of the patient at the date of the flutter ablation

GenderOne day

Gender of the patient at the date of the flutter ablation

Antecedents of ischemic cardiomyopathyOne day

Antecedents of ischemic cardiomyopathy (yes/no) at the date of flutter ablation

Antecedents of dilated cardiomyopathyOne day

Antecedents of dilated cardiomyopathy (yes/no) at the date of flutter ablation

Chronic pulmonal diseaseOne day

Chronic pulmonal disease diagnosed at the date of flutter ablation

Stroke after flutter ablationOne year

Occurence of stroke after the flutter ablation

DiabetesOne day

Diabetes diagnosis (yes/no) at the date of flutter ablation

Arterial hypertensionOne day

Presence of arterial hypertension on the day of flutter ablation

Antecedents of strokeOne day

Antecedents of stroke

Antecedents of peripheric thromboembolic eventsOne day

Antecedents of thromboembolic events on the day of flutter ablation

Antecedents of cardiomyopathyOne day

Antecedents of cardiomyopathy (yes/no) at the date of flutter ablation

Atrial fibrillation antecedentsOne day

Antecedents of Atrial fibrillation at the date of flutter ablation

Peripheric thromboembolic events after flutter ablationOne year

Thromboembolic events after flutter ablation

Left ventricular ejection fraction of the heartOne day

Left ventricular ejection fraction of the heart at the day of flutter removal (echographic data)

Beta-blockers post-ablationOne day

Prescription of Beta-Blockers after the flutter ablation (yes/no)

Amiodarone post-ablationOne year

Prescription of amiodarone after the flutter ablation (yes/no)

Left atrium size of the heartOne day

Left atrium size of the heart at the day of flutter removal (echographic data)

Class I antiarrhythmic drugs post-ablationOne year

Prescription of Class I antiarrhythmic drugs post-ablation

Pulmonary arterial pressureOne day

Pulmonary arterial pressure at the day of flutter removal (echographic data)

Atrial Fibrillation apparition delayUp to one year

Delay of apparition of atrial fibrillation after flutter removal

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

CHU Brugmann

🇧🇪

Brussels, Belgium

CHU Brugmann
🇧🇪Brussels, Belgium
© Copyright 2025. All Rights Reserved by MedPath